2022 Fiscal Year Annual Research Report
Mechanistic analysis of the PD-1 blockade combination cancer immunotherapy with BTK inhibitors.
| Project/Area Number |
21F20405
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
本庶 佑 京都大学, 医学研究科, 特任教授 (80090504)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ZOU YIXIN 京都大学, 医学研究科, 外国人特別研究員
|
|---|
| Project Period (FY) |
2021-04-28 – 2023-03-31
|
| Keywords | BTK inhibitor / Xbp1s / CD8+ T cells |
|---|
| Outline of Annual Research Achievements |
Acalabrutinib could change the metabolic patterns of CD8+ T cells in vivo, but failed in vitro. Both BTK inhibitors could reduce UPR genes expression in CD8+ T cells, especially for Xbp1s. The expression of Xbp1s was up-regulated in tumor-infiltrating CD8+ T cells compared with those from DLNs and tumor-free LNs. In addition, the Xbp1s expression showed negative correlation with Ifng, Gzmb and Prf1 in tumor-infiltrating CD8+ T cells. Similarly, in vitro experiments revealed that Xbp1s overexpressed CD8+ T cells had lower levels of interferon-gamma, granzyme B and perforin than wild type. By analyzing the GEO dataset GSE118430, we found that Xbp1 KO CD4+ T cells showed relatively high expression of several genes associated with T cells immune response such as Ifng, Ccl5, Cxcr5, etc.
|
| Research Progress Status |
令和4年度が最終年度であるため、記入しない。
|
| Strategy for Future Research Activity |
令和4年度が最終年度であるため、記入しない。
|
